Renal denervation for treatment of drug-resistant hypertension. Trends Cardiovasc Med 2015 Feb;25(2):107-115.
Renal nerve ablation for resistant hypertension: how did we get here, present status, and future directions. Circulation 2014 Apr;129(13):1440-1451.
Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009 Apr;373(9671):1275-1281.
Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 2013 Jul;128(2):132-140.
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010 Dec;376(9756):1903-1909.
A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014 Apr;370(15):1391-1401.
Is the failure of Symplicity HTN-3 trial to meet its efficacy endpoint the “end of the road” for renal denervation? J Am Soc Hypertens 2015 Feb;9(2):140-149.
Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings. J Am Soc Hypertens 2014 Aug;8(8):593-598.
Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system. Hypertension 2014 Sep;64(3):565-572.
Carotid baroreceptor stimulation: a promising approach for the management of resistant hypertension and heart failure. Curr Vasc Pharmacol 2014 Jan;12(1):30-37.
Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010 Mar;55(3):619-626.
Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos pivotal trial. J Am Coll Cardiol 2011 Aug;58(7):765-773.
Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens 2012 Mar-Apr;6(2):152-158.
Baroreflex activation therapy for the treatment of drug-resistant hypertension: new developments. Cardiol Res Pract 2012;2012:587194.
Median nerve modulation: a novel approach to resistant hypertension. J Am Coll Cardiol Interv 2016;9(4_S):S54.
Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomized controlled trial. Lancet 2015 Apr;385(9978):1634-1641.
Effects of arteriovenous fistula formation on arterial stiffness and cardiovascular performance and function. Nephrol Dial Transplant 2011 Oct;26(10):3296-3302.
